Your browser doesn't support javascript.
loading
Heart failure therapy in diabetic patients-comparison with the recent ESC/EASD guideline.
Edelmann, Frank; Wachter, Rolf; Düngen, Hans-Dirk; Störk, Stefan; Richter, Annette; Stahrenberg, Raoul; Neumann, Till; Lüers, Claus; Angermann, Christiane E; Mehrhof, Felix; Gelbrich, Götz; Pieske, Burkert.
Afiliação
  • Edelmann F; Department of Cardiology and Pneumology, University of Göttingen, Göttingen, Germany. fedelmann@med.uni-goettingen.de
Cardiovasc Diabetol ; 10: 15, 2011 Feb 08.
Article em En | MEDLINE | ID: mdl-21303531
ABSTRACT

BACKGROUND:

To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function.

METHODS:

3304 patients with heart failure from 9 different studies were included (mean age 63 ± 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (≥ 50%) and 994 patients in the whole cohort suffered from diabetes.

RESULTS:

The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function.

CONCLUSIONS:

Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Função Ventricular Esquerda / Disfunção Ventricular Esquerda / Complicações do Diabetes / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Cardiovasculares / Função Ventricular Esquerda / Disfunção Ventricular Esquerda / Complicações do Diabetes / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2011 Tipo de documento: Article